Day Gain | ||
Gain | ||
Market Val | ||
Costs | ||
Cash | ||
Portfolio | ||
Realized | ||
Dividend |
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2024-11-07 | 2024-09 | -1.85 | N/A | N/A | N/A |
2024-08-01 | 2024-06 | -3.47 | -3.33 | 0.14 | 4.03% |
2024-05-02 | 2024-03 | -3.59 | -3.07 | 0.52 | 14.48% |
2024-05-02 | 2024-03 | -3.59 | N/A | N/A | N/A |
2024-02-22 | 2023-12 | -0.78 | 0.55 | 1.33 | 170.51% |
2024-02-22 | 2023-12 | -0.78 | N/A | N/A | N/A |
Date | Firm | Action | From | To |
---|---|---|---|---|
2023-09-12 | Argus Research | Upgrade | Buy | Buy |
2023-08-03 | TD Cowen | Downgrade | Outperform | Market Perform |
2023-08-03 | RBC Capital | Upgrade | Outperform | Outperform |
2023-08-03 | B of A Securities | Upgrade | Neutral | Neutral |
2023-08-03 | Morgan Stanley | Upgrade | Equal-Weight | Equal-Weight |
2023-08-02 | Deutsche Bank | Downgrade | Buy | Hold |
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2024-07-30 | AFEYAN NOUBAR BOGHOS | Director | 6.86M | Sale |
2022-12-27 | ANDRES JUAN | Chief Technology Officer | 12.80K | Sale |
2024-02-15 | BANCEL STEPHANE J | Chief Executive Officer | 21.08M | Sale |
2024-05-02 | BERENSON STEPHEN A. | Director | 22.20K | Conversion of Exercise of derivative security |
2023-12-05 | GARAY ARPA | Officer | 3.69K | Sale |
2024-09-02 | HOGE STEPHEN | President | 1.60M | Sale |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Baillie Gifford and Company | 45.71M | 5.55B | 12.01% |
2023-06-29 | Vanguard Group Inc | 27.46M | 3.34B | 7.22% |
2023-06-29 | Blackrock Inc. | 24.16M | 2.94B | 6.35% |
2023-06-29 | State Street Corporation | 14.23M | 1.73B | 3.74% |
2023-06-29 | Flagship Pioneering Inc. | 12.89M | 1.57B | 3.39% |
2023-06-29 | Coatue Management LLC | 6.55M | 795.35M | 1.72% |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Vanguard Total Stock Market Index Fund | 10.11M | 1.23B | 2.66% |
2023-05-30 | Vanguard International Growth Fund | 9.42M | 1.20B | 2.47% |
2023-06-29 | Vanguard 500 Index Fund | 7.81M | 948.38M | 2.05% |
2023-08-30 | Invesco ETF Tr-Invesco QQQ Tr, Series 1 ETF | 6.46M | 730.48M | 1.70% |
2023-07-30 | Vanguard Specialized-Health Care Fund | 4.45M | 523.90M | 1.17% |
2023-05-30 | Fidelity 500 Index Fund | 3.70M | 472.16M | 0.97% |
Split | Date |
---|---|
1 : 10 | 2017-08-03 |
-
Hold your stocks, the future is bright and very rewarding. Look how $MRNA PE will change from last year to 2021.
Forecast P/E Growth Rates
Growth 2020 $-0.65
Growth 2021 $1044.87
P/E Ratios 2020 -102.16
P/E Ratios 2021 10.81 -
The number of shares shorted decreased from 23.39M to 19.98M
Institutions owned 52% and insiders 10%.
The rest 38% is owned by us the small investors -
-
The market being red is one thing. The 50% production increase without any extra investment. It is the best news!!! This will allow $MRNA to make and sell more vaccines in shorter time., which translates to more $$$ billions.
-
The earnings run is about to start today.!!!
-
$PFE Pfizer plans to increase the weekly shipments of Pfizer-BioNTech's Covid-19 vaccine to more than 13 million doses, while $MRNA Moderna is aiming to supply 40 million doses.
Both companies have plans to complete the 300M doses contracted with the US by the end of July.
That means HUGE earnings for the first 2 quarter of the year. -
The bears are really hard to get it to $150 for earnings. That way way we might nor see the $200s on earnings day.
-
The stop loses of $165 got triggered and now the $164.
-
$168.37 coming in the next 10 min
-
PFE Already started to go back up. MRNA should follow
-
No, don’t check out any of those stock
-
Moderna expects to deliver 100 million doses to the U.S. Government by end of March 2021
Moderna expects to deliver 100 million additional doses by end of May 2021 followed by another 100 million additional doses by end of July 2021
That is more than $4.5B !!! just from the US contracts alone!!! Add to that the international contracts. Last year they were reporting Millions in loses, an d this year they will be reporting Billions in gains.$MRNA PE ratio will change dramatically causing the stock to shoot up on earnings days. Moderna will use the new found fortune to expand and bring other vaccines to the markets. The COVID vaccine it is just the first one to many more they have in the pipeline.
The stock price will double by the end of 2021 -
MRNA. Patient my friends. Patients.
I’m BULL. !! Oh yea!!
-
This is. Absolutely ridiculous.
What ?????
150 m dose more and it’s going DOWN ??????????What is going on ?!?!?!
-
OCGN ️
-
11 minutes to get over the $186!!!!!
-
OCGN is a piece of . In the last 5 years lost 99.9999% of the money of its investors. Now they want to say, oh we are doing so good, we just went from pennies to $10. That is just because it just recovered 2% of their 99.999% loses from the last 5 years. They really are a piece of . If you for some reason likes it. Go ahead and stop posting here your stock.
-
There is low volume because the so call brokers are not allowing people to buy. That is why.
-
The stupid bears have wasted 2 weeks of our time with $MRNA. What a ball of they are.
-
They only are allowing me to buy 50 shares when I have money to buy more than 1000 shares.
Is any of you having this problem?
-
NTx Services Launches to Supercharge Next Generation mRNA Research
businesswire.com • -
Moderna (NASDAQ:MRNA) Shares Up 7%
news.google.com • -
Moderna (NASDAQ:MRNA) PT Lowered to $48.00
news.google.com • -
What's Going On With Moderna Shares Tuesday?
news.google.com • -
Where are the Opportunities in (MRNA)
news.google.com • -
MODERNA, INC. (NASDAQ: MRNA) DEADLINE ALERT: Bernstein
news.google.com • -
Moderna: Cutting Costs At Just The Worst Time (NASDAQ:MRNA)
news.google.com • -
Class Action Lawsuit Against Moderna, Inc. (NASDAQ:MRNA)
news.google.com • -
After Moderna's Shocking News, Is the Stock a Buy or a Sell?
news.google.com • -
Moderna Gets Analyst Downgrade After $1.1B R&D Spending Cut
news.google.com • -
‘Time to Move to the Sidelines,’ Says Jefferies About Moderna Stock
news.google.com • -
MRNA Stock Falls 12% on Lowered Sales Outlook, R&D Budget Cuts
news.google.com • -
Biotech Stocks Are Tumbling — But The Top 5 Are Standouts
news.google.com • -
Moderna's Move Shows Lack Of Confidence, Shrinks Pipeline (NASDAQ:MRNA)
news.google.com • -
Moderna Stock Falls Again. How the Drug Maker Can Turn Things Around.
news.google.com • -
Moderna: Oddo BHF reduces its target after CMD
news.google.com • -
Moderna (NASDAQ:MRNA) Stock Falls 12% as R&D Budget Is Cut by $1B
news.google.com • -
Moderna Slashes R&D Budget, Stock Plummets Amid Profitability Concerns
news.google.com • -
Moderna Stock Plummets on Cost-Cutting Measures
news.google.com • -
Biggest stock movers today: WBD, MPW, MRNA, SIG, and more
news.google.com • -
Moderna Stock Drops on Plans To Cut $1.1B in R&D Costs
news.google.com •